Offering circular

Cabbacis Adds Equity Crowdfunding Platform for IPO

Retrieved on: 
Wednesday, December 13, 2023

Cabbacis Inc (“Cabbacis” or the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that investors can now participate in the Company’s Regulation A (Tier 2) initial public offering (IPO) through a capital raising portal.

Key Points: 
  • Cabbacis Inc (“Cabbacis” or the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that investors can now participate in the Company’s Regulation A (Tier 2) initial public offering (IPO) through a capital raising portal.
  • The Company has strategically chosen Issuance as its Regulation A, equity crowdfunding, platform portal.
  • The Issuance platform conveniently accepts credit cards, debit cards, American Express, Apple Pay, Google Pay, ACH (bank-to-bank), or wire transfers for investments.
  • Subsequent to the closing of the Offering, Cabbacis will be applying to FINRA and OTC Markets Group to list its common stock on the OTCQB® Venture Market.

Cabbacis Announces IPO Via Regulation A

Retrieved on: 
Tuesday, November 14, 2023

Cabbacis Inc (“Cabbacis” or the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that the Company has launched a $5 million, Regulation A (Tier 2), initial public offering.

Key Points: 
  • Cabbacis Inc (“Cabbacis” or the “Company”), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that the Company has launched a $5 million, Regulation A (Tier 2), initial public offering.
  • Yesterday the U.S. Securities and Exchange Commission (“SEC”) qualified the Company’s Form 1-A Offering Circular which was filed with the SEC on October 20th.
  • The offering will be on a best-efforts basis through the website, www.cabbacis.com , where the Offering Circular is posted on the “Investors” page.
  • Subsequent to the closing of the offering, Cabbacis will be applying to FINRA and OTC Markets Group to list its common stock on the OTCQB® Venture Market.

Bank of Bird-in-Hand Reports on Progress of Stock Offering

Retrieved on: 
Tuesday, October 31, 2023

The Bank of Bird-in-Hand (the “Bank”) announced that, as of October 26, 2023, it has received subscriptions for 514,635 shares of its common stock for aggregate gross proceeds of $14,409,780 before deducting offering expenses, through the previously announced stock offering of its shares of common stock.

Key Points: 
  • The Bank of Bird-in-Hand (the “Bank”) announced that, as of October 26, 2023, it has received subscriptions for 514,635 shares of its common stock for aggregate gross proceeds of $14,409,780 before deducting offering expenses, through the previously announced stock offering of its shares of common stock.
  • The Bank commenced the common stock offering on September 18, 2023, at $28.00 per share, of up to approximately $15 million of common stock with the right to increase the offering amount up to approximately $30 million, at the sole discretion of the Board of Directors in the event that demand for the shares exceeded $15 million.
  • Kevin J. McClarigan, CPA, Chairman of the Board, stated, “We are excited and humbled by the strong demand we have experienced for our latest common stock offering.
  • The Bank reserves the right, however, to withdraw or terminate the Offering at any time and return unaccepted subscriptions to subscribers.

Sabre Corporation Announces Early Participation Results of the Exchange Offers for Certain Senior Secured Debt Securities

Retrieved on: 
Monday, August 21, 2023

Any waiver of a condition by Sabre GLBL will not constitute a waiver of any other condition.

Key Points: 
  • Any waiver of a condition by Sabre GLBL will not constitute a waiver of any other condition.
  • Sabre GLBL reserves the right to extend, amend or terminate any Exchange Offer for any reason or for no reason.
  • Sabre GLBL will not receive any cash proceeds from the Exchange Offers and will not incur additional indebtedness in excess of the aggregate principal amount of Existing Notes that are exchanged in the Exchange Offers.
  • Only Eligible Holders are authorized to receive or review the Offering Circular or to participate in the Exchange Offers.

Sabre Corporation Announces Exchange Offers by Sabre GLBL Inc. for Certain Senior Secured Debt Securities

Retrieved on: 
Monday, August 7, 2023

The New Notes and the guarantees thereof will be senior secured indebtedness and will rank equal in right of payment with all of the existing and future senior secured indebtedness of Sabre GLBL and the guarantors.

Key Points: 
  • The New Notes and the guarantees thereof will be senior secured indebtedness and will rank equal in right of payment with all of the existing and future senior secured indebtedness of Sabre GLBL and the guarantors.
  • The New Notes will initially be jointly and severally, irrevocably and unconditionally guaranteed by Sabre Holdings Corporation ("Sabre Holdings") and all of Sabre GLBL's current and future restricted subsidiaries that are borrowers under or guarantee Sabre GLBL's senior secured credit facilities under certain of its existing credit agreements or certain other secured indebtedness.
  • Sabre GLBL reserves the right to extend, amend or terminate any Exchange Offer for any reason or for no reason.
  • Sabre GLBL will not receive any cash proceeds from the Exchange Offers and will not incur additional indebtedness in excess of the aggregate principal amount of Existing Notes that are exchanged in the Exchange Offers.

Startup Invest Inc. Introduces Revolutionary Machine-Learning Investment Platform

Retrieved on: 
Monday, July 3, 2023

Alongside this milestone, Invest Inc. is proud to introduce their groundbreaking retail data platform, Invest.inc.

Key Points: 
  • Alongside this milestone, Invest Inc. is proud to introduce their groundbreaking retail data platform, Invest.inc.
  • This innovative platform leverages machine learning to deliver personalized institutional-level market information and tools, empowering retail investors to make well-informed investment decisions.
  • With a strong focus on democratizing access to valuable insights, Invest.inc goes beyond traditional retail investment platforms.
  • To further enhance the platform's monetization strategy, Invest.inc offers advertisers and public issuers a self-serve AI-driven advertising and media-buying platform.

Startup Invest Inc. Launches First of its Kind Machine-Learning Investment Platform

Retrieved on: 
Thursday, June 29, 2023

This innovative platform grants users access to a wealth of valuable data at little to no cost, making it an essential tool for every investor.

Key Points: 
  • This innovative platform grants users access to a wealth of valuable data at little to no cost, making it an essential tool for every investor.
  • Building on the success of their groundbreaking platform, Invest Inc. has announced an exciting new development in their mission to level the playing field.
  • In addition, Invest Inc. is launching their first ever paper trading tournament, hosted on the Invest Inc. Terminal with a substantial $200k cash prize pool for the top performers.
  • Founded in 2020, Invest Inc. is a Wyoming-based fintech adtech investment research platform.

COMPLETION OF CONTRIBUTION OF FIRMENICH SHARES TO DSM-FIRMENICH

Retrieved on: 
Tuesday, May 9, 2023

KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 9, 2023 /PRNewswire/ -- DSM-Firmenich AG (the Company or DSM-Firmenich) announces that the Firmenich Contribution took place yesterday, thereby completing the transactions contemplated by the merger of equals between DSM and Firmenich.

Key Points: 
  • KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 9, 2023 /PRNewswire/ -- DSM-Firmenich AG (the Company or DSM-Firmenich) announces that the Firmenich Contribution took place yesterday, thereby completing the transactions contemplated by the merger of equals between DSM and Firmenich.
  • As a result of the Firmenich Contribution, Firmenich is now a wholly owned subsidiary of DSM-Firmenich.
  • The aggregate consideration received by the Firmenich Shareholders through the Firmenich Contribution is:
    an amount in cash of EUR 3.5 billion; plus
    91,658,354 newly issued DSM-Firmenich Ordinary Shares, representing 34.5% of the Company's total of 265,676,388 aggregate issued DSM-Firmenich Ordinary Shares as of today.
  • Any joint press release issued by the Company, DSM and Firmenich is made available on the website of the Company ( www.dsm-firmenich.com ).

FINAL RESULTS OF THE EXCHANGE OFFER: 96.1% OF DSM ORDINARY SHARES TENDERED

Retrieved on: 
Monday, May 1, 2023

KAISERAUGST, Switzerland and HEERLEN, Netherlands and GENEVA, May 1, 2023 /PRNewswire/ -- 

Key Points: 
  • DSM Shareholders who have validly tendered (or defectively tendered, provided that such defect has been waived by the Company) and transferred (geleverd) their DSM Ordinary Shares for acceptance in the Exchange Offer during the Post-Acceptance Period, will receive the Offer Consideration in respect of each tendered DSM Ordinary Share on 3 May 2023 (the Post-Closing Acceptance Settlement Date).
  • The Company accepts all DSM Ordinary Shares that have been validly tendered (or defectively tendered, provided that such defect has been waived by the Company) pursuant to the terms of the Exchange Offer.
  • In addition, DSM will procure the termination of the listing and trading of DSM Ordinary Shares on Euronext Amsterdam as soon as practicable.
  • If a beneficiary to DSM Ordinary Shares located in the United States is unable to make the QIB Confirmations on behalf of itself or the person on whose behalf such DSM Ordinary Shares are held, any DSM-Firmenich Ordinary Shares allotted to such person will instead be transferred to a sales agent, and such DSM-Firmenich Ordinary Shares will be sold on his, her or its behalf with the proceeds being remitted to such person within five days of the Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during the Acceptance Period, or within five days of the Post-Closing Acceptance Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during any Post-Closing Acceptance Period.

FINAL RESULTS OF THE EXCHANGE OFFER: 96.1% OF DSM ORDINARY SHARES TENDERED

Retrieved on: 
Monday, May 1, 2023

KAISERAUGST, Switzerland, HEERLEN, the Netherlands and GENEVA, May 1, 2023 /PRNewswire/ -- DSM-Firmenich AG (the Company or DSM-Firmenich), DSM, and Firmenich are pleased to announce that during the Post-Closing Acceptance Period, which expired on 28 April 2023 at 17:40 CEST, 16,578,846 DSM Ordinary Shares have been tendered for acceptance in the Exchange Offer, representing approximately 9.6% of DSM's aggregate issued and outstanding ordinary share capital and an aggregate value of approximately EUR 1.97 billion.1 Together with the DSM Ordinary Shares already held by the Company on the date hereof, the Company will hold a total of 167,321,557 DSM Ordinary Shares, representing approximately 96.1% of DSM's aggregate issued and outstanding ordinary share capital.

Key Points: 
  • DSM Shareholders who have validly tendered (or defectively tendered, provided that such defect has been waived by the Company) and transferred (geleverd) their DSM Ordinary Shares for acceptance in the Exchange Offer during the Post-Acceptance Period, will receive the Offer Consideration in respect of each tendered DSM Ordinary Share on 3 May 2023 (the Post-Closing Acceptance Settlement Date).
  • The Company accepts all DSM Ordinary Shares that have been validly tendered (or defectively tendered, provided that such defect has been waived by the Company) pursuant to the terms of the Exchange Offer.
  • In addition, DSM will procure the termination of the listing and trading of DSM Ordinary Shares on Euronext Amsterdam as soon as practicable.
  • If a beneficiary to DSM Ordinary Shares located in the United States is unable to make the QIB Confirmations on behalf of itself or the person on whose behalf such DSM Ordinary Shares are held, any DSM-Firmenich Ordinary Shares allotted to such person will instead be transferred to a sales agent, and such DSM-Firmenich Ordinary Shares will be sold on his, her or its behalf with the proceeds being remitted to such person within five days of the Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during the Acceptance Period, or within five days of the Post-Closing Acceptance Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during any Post-Closing Acceptance Period.